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ABSTRACT
Introduction: The anti-anginal efficacy of
ivabradine is well established. We describe a
post hoc analysis in the ADDITIONS database to
investigate effectiveness and tolerability of
ivabradine in combination with beta-blocker
in patients with angina who have had a
percutaneous coronary intervention (PCI).
Methods: ADDITIONS was a non-
interventional, multicenter prospective study
including 2,330 patients with stable angina. In
addition to beta-blocker, patients were treated
with ivabradine in approved dosages for
4 months. We divided the population
according to whether they had previously had
a PCI or not, and explored the effect of
ivabradine on heart rate, number of weekly
angina attacks, frequency of nitrate
consumption, as well as quality of life (QoL)
and tolerability.
Results: Data were available for 2,319 patients,
of whom 51.4% had previously had a PCI. There
was no difference in the effect of ivabradine on
mean heart rate between patients with a
previous PCI [64.4 ± 7.6 beats per minute
(bpm)] than those without (66.8 ± 8.5 bpm) at
4 months (both P\0.0001). Similarly, the
number of angina attacks decreased from
1.9 ± 2.4 to 0.5 ± 1.5 per week in patients with
a previous PCI and 1.5 ± 2.0 to 0.3 ± 1.0 per
week in patients without a previous PCI (both
P\0.0001). The frequency of nitrate
consumption fell from 2.7 ± 3.7 to 1.0 ± 1.9
per week and 1.8 ± 2.8 to 0.6 ± 1.5 per week
(both P\0.0001) in patients with and without a
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previous PCI, respectively. There was no
difference in the improvements in Canadian
Cardiovascular Society class of angina, QoL, and
physicians’ assessment of effectiveness and
tolerability between patients with a previous
PCI and those without.
Conclusion: Ivabradine is an effective and well-
tolerated anti-anginal treatment in patients
with stable angina after PCI. Ivabradine
reduced the frequency of weekly angina
attacks and nitrate consumption, led to an
improvement in Canadian Cardiovascular
Society class and a substantial improvement in
the QoL of stable angina patients.
Keywords: Angina pectoris; Cardiology;
Ivabradine; Percutaneous coronary
intervention; Quality of life
INTRODUCTION
Coronary artery disease (CAD) leads to the
death of more than seven million people each
year worldwide [1]. Guidelines for the treatment
of CAD strongly encourage the use of optimal
medical therapy as a first step in its
management [2, 3]. Percutaneous coronary
intervention (PCI) is also frequently used in
the management of CAD to relieve symptoms of
angina. Registry data suggest that more than
half of CAD patients have undergone a PCI,
though this figure can vary depending on sex
and geographical location [4, 5].
Angina pectoris is a common symptom of
CAD and affects around 112 million people
globally [6]. PCI has been shown to
substantially reduce angina symptoms
particularly in patients with severe angina [7–
9]. However, a randomized clinical study,
COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug
Evaluation; ClinicalTrials.gov #NCT00007657),
showed that the benefits of PCI regarding
quality of life (QoL) can be short term [10]
and that angina symptoms can persist in many
patients after PCI [11–13]. In a study including
post-myocardial infarction (MI) patients,
angina symptoms were reported to have
occurred more frequently after 1 year in
patients with a clinical history of PCI (25.2%)
than in those without (15.4%) [13]. COURAGE
also showed that complementing optimal
medical therapy with PCI does not lessen the
risk of death, MI, or other major cardiovascular
events in comparison to medical therapy alone,
and may have no long-term or additional
cardiovascular benefits [14]. More recent meta-
analyses of randomized trials comparing PCI
and medical therapy in patients with CAD
showed that PCI did not reduce the risk of
mortality, non-fatal MI, or revascularization
[15, 16]. Two-year results from the FAME II
(ClinicalTrials.gov #NCT01132495) trial
showed a significant reduction in urgent
revascularizations after fractional flow reserve-
guided PCI plus medical therapy compared with
medical therapy alone, but also with no
significant effect on mortality or MI [17].
These results may indicate a relevance of
objective assessment of ischemia in patients
with PCI to improve outcomes.
Optimal medical therapy is currently under-
prescribed for symptomatic CAD patients and
less than half benefit from such an approach
prior to PCI [18]. One such medical therapy,
ivabradine, lowers heart rate by reducing the
activity of the cardiac pacemaker through
inhibition of the If current, which in turn
decreases cardiac workload and myocardial
oxygen consumption [19]. It is effective at
reducing ischemia and symptoms of angina
[20–23]. The ADDITIONS (PrActical Daily
efficacy anD safety of Procoralan In
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combinaTION with betablockerS; Controlled-
Trials.com #ISRCTN53233058) trial [24] showed
that treating patients with stable angina with a
combination of ivabradine and beta-blocker
reduces heart rate, angina attacks, and nitrate
consumption and improves Canadian
Cardiovascular Society (CCS) classification
along with QoL. Due to the fact that angina
symptoms can persist in many patients after
PCI, leading to significant impairment in QoL
[10–13], we aimed to evaluate ivabradine as an
option for such patients with high resting heart
rate. In this paper, we present a post hoc
analysis of ADDITIONS that assesses the effect
of ivabradine as part of a medical therapy when
treating stable angina in patients with a clinical
history of PCI at baseline.
METHODS
Study Design
ADDITIONS was a 4-month, non-
interventional, prospective, open-label
multicenter trial. A more detailed description
of the methods used in the ADDITIONS trial is
given by Werdan et al [24]. A total of 2,330
patients with stable angina pectoris were
included in 818 centers in Germany.
Investigators, comprising physicians
specialized in internal medicine, general
practitioners, or cardiologists in private
practice, filled out a standardized
questionnaire at each visit during the trial.
Patients with symptomatic chronic stable
angina pectoris under current beta-blocker
therapy were eligible for inclusion into the
study. To be suitable for treatment with
ivabradine, patients also had to have one of
the following: (1) angina pectoris that was
insufficiently controlled with beta-blocker
alone or (2) insufficient effectiveness of—or
intolerance to—another anti-anginal medicine
leading to a change in treatment. Only patients
who had given their written consent and who
met the inclusion and exclusion criteria were
eligible for inclusion. Patients commenced
ivabradine treatment at 5 mg, twice daily. At
the investigator’s discretion, after 4 weeks, the
dose could be increased to 7.5 mg, twice daily.
For patients aged C75 years or with resting heart
rate \50 beats per minute (bpm) at follow-up
visits, investigators also had the option of
prescribing a lower dose of 2.5 mg, twice daily.
The physician was free to change the ivabradine
dose during the trial if considered necessary.
This study was carried out in accordance
with the Declaration of Helsinki and in
agreement with the ethical guidelines of the
European Independent Ethics Committee.
Ethical approval was granted by the ethical
commission of Martin-Luther-University Halle-




There were three visits (at baseline, and around
1 and 4 months after baseline) programmed
during this trial. At baseline, parameters
including general medical and cardiovascular
history (previous MI or revascularization using
PCI), cardiac risk factors, concomitant diseases,
and medication were recorded. Heart rate, the
incidence of angina attacks (within the previous
week), and the frequency of use of short-acting
nitrates (within the previous week) in patients
were documented at baseline and after 1 and
4 months. Patient QoL was also recorded using
an EQ-5D questionnaire (single scores
summarized using the EQ-5D index score) at
each visit [25]. Information relating to safety
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such as suspected adverse drug reactions,
reasons for discontinuing ivabradine and
changes in concomitant medication was
recorded after 1 and 4 months. The
effectiveness and tolerance of ivabradine was
further assessed by the treating physician and
categorized into ‘‘very good’’, ‘‘good’’,
‘‘moderate’’, or ‘‘poor’’. Due to the non-
interventional design of the study, the
participating physicians were free to initiate
any intervention they considered appropriate
for the individual patient.
Analysis
In this post hoc analysis of the ADDITIONS
population, we divided the population
according to whether they had previously had
a PCI or not. In the two subgroups, we evaluated
the effect of ivabradine on heart rate and
assessed its impact upon the incidence of
angina attacks, frequency of use of short-
acting nitrates, angina classification using the
CCS class, and QoL using the EQ-5D index and
visual analog scale (VAS) score. The previous
PCI subgroup population was also divided
according to whether patients had a baseline
heart rate of \70 bpm or C70 bpm. The impact
of ivabradine on the incidence of angina
attacks, frequency of use of short-acting
nitrates rate and heart rate in these two
subgroups was then evaluated, and the mean
daily dose of ivabradine was reported.
Statistics
The analysis of the data is essentially descriptive
and was performed using SAS software (version
9.1; SAS Institute Inc., Cary, NC, USA). Absolute
and relative changes were calculated for
continuous variables such as heart rate,
number of angina attacks, consumption of
short-acting nitrates and EQ-5D score, and
described using the arithmetic mean and
standard deviation. Details are given in
Werdan et al [24]. Absolute changes of values
between baseline and follow-up visits were
assessed using Wilcoxon’s signed-rank test and




Of the 2,330 patients who participated in the
ADDITIONS study, 11 were not included in this
post hoc analysis as their PCI status had not
been recorded. Among the 2,319 patients with a
recorded PCI status (Table 1), 51.4% had
previously had a PCI. Two-thirds (67%) of the
patients with PCI were male vs. 49% in patients
without PCI. The mean age was 65.8 ± 9.9 years
and 66.0 ± 11.5 years in patients with and
without a previous PCI, respectively. The
majority of patients with previous PCI had
only one previous PCI (56%). Patients with a
previous PCI status were more likely to have a
history of MI, hypertension, dyslipidemia,
diabetes, and peripheral artery disease (PAD),
but less likely to have chronic obstructive
pulmonary disease (COPD) or asthma. The
mean resting heart rate was slightly lower in
patients with a previous PCI than without
(83.1 ± 11.0 bpm vs. 87.0 ± 13.2 bpm,
respectively). The number of angina attacks
was slightly higher in patients with a PCI
status than without (1.9 ± 2.4 vs.1.5 ± 2.0 per
week, respectively). A similar trend was
observed in the use of nitrates (2.7 ± 3.7 vs.
1.8 ± 2.8 per week, respectively). A lower
proportion of patients in the previous PCI
subgroup were classified as CCS class I or II
(75%), in comparison with the no previous PCI
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Table 1 Baseline characteristics of the stable CAD population with angina in ADDITIONS according to PCI status
Characteristic Patients with previous
PCI (n5 1,193)
Patients with no previous
PCI (n5 1,126)
Demographic characteristics
Age (years) 65.8 ± 9.9 66.0 ± 11.5
Men 803 (67%) 547 (49%)
Body mass index (kg/m2) 28.1 ± 4.3 28.5 ± 4.9
Medical history
Previous PTCA with stent (PCI)
One 669 (56%) –
Two or more 311 (26%) –
Unknown 213 (18%) –
Previous myocardial infarction 681 (58%) 157 (13%)
Hypertension 1,072 (90%) 988 (88%)
Dyslipidemia 889 (75%) 638 (57%)
Diabetes mellitus 409 (34%) 368 (33%)
Peripheral artery disease 125 (10%) 79 (7%)
COPD 171 (14%) 173 (15%)
Asthma 37 (3%) 76 (7%)
Cardiovascular medication
Beta-blockers 1,193 (100%) 1,126 (100%)
ACE inhibitors 698 (59%) 500 (44%)
AT1 antagonists 341 (29%) 319 (28%)
Calcium antagonists 244 (20%) 185 (16%)
Long-acting nitrates/molsidomin 374 (31%) 204 (18%)
Ranolazine 12 (1%) 4 (\1%)
Diuretics 477 (40%) 398 (35%)
Aspirin 1,059 (89%) 804 (71%)
Clopidogrel 336 (28%) 84 (7%)
Statins 1,001 (84%) 689 (61%)
Clinical ﬁndings
Heart rate (bpm) 83.1 ± 11.0 87.0 ± 13.2
Weekly number of angina attacks 1.9 ± 2.4 1.5 ± 2.0
Weekly use of nitrates 2.7 ± 3.7 1.8 ± 2.8
Systolic blood pressure (mm Hg) 135.1 ± 15.1 140.0 ± 16.1
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subgroup (86%). At baseline, the EQ-5D scores
were similar in patients with and without a
previous PCI at 0.65 ± 0.28 and 0.68 ± 0.26,
respectively (Table 1). The EQ-5D VAS scores
were also comparable at 56.2 ± 18.1 and
58.7 ± 18.5 for previous PCI and no previous
PCI, respectively.
Beta-Blocker Dosage
Every patient in the study was prescribed
optimal dosages of beta-blocker at the
discretion of the investigator. Metoprolol and
bisoprolol were prescribed for the majority of
patients, at similar rates in the two subgroups
(previous PCI, 45% and 36%, respectively; no
previous PCI, 41% and 39%, respectively) and at
similar doses (previous PCI, 110.6 ± 50.6 mg
and 7.2 ± 3.4 mg, respectively; no previous
PCI, 101.5 ± 48.9 mg and 6.8 ± 3.5 mg,
respectively). Other beta-blockers, which were
prescribed for \13% of patients in each
subgroup, in decreasing order of frequency
were, nebivolol, carvedilol, and atenolol. The
recommended maximum beta-blocker doses
were defined for metoprolol at 190 mg/day,
bisoprolol and nebivolol each at 10 mg/day,
and atenolol and carvedilol each at 100 mg/day.
A slightly higher proportion of patients in the
previous PCI subgroup (81%) were taking C50%
to \100% or C100% of the recommended
maximum doses in comparison with the no
previous PCI group (75%).
Effect of Ivabradine
At baseline, patients with and without a
previous PCI were on comparable doses of
ivabradine (mean daily dose, 9.6 ± 1.3 mg/day
and 9.5 ± 1.6 mg/day, respectively). An initial
rapid decrease in heart rate was similarly
observed in both subgroups over the first
month (Fig. 1). The heart rate of patients with
a previous PCI decreased from 83.1 ± 11.0 bpm
Table 1 continued
Characteristic Patients with previous
PCI (n5 1,193)
Patients with no previous
PCI (n5 1,126)
Diastolic blood pressure (mm Hg) 81.5 ± 9.3 83.5 ± 9.5
Ejection fraction (%) 54.9 ± 12.9 57.2 ± 12.9
Canadian Cardiovascular Society class
Class I 214 (20%) 391 (40%)
Class II 609 (55%) 452 (46%)
Class III 264 (24%) 139 (14%)
Class IV 12 (1%) 4 (\1%)
Quality of life
Visual analog scale 56.2 ± 18.1 58.7 ± 18.5
Quality of life index 0.65 ± 0.28 0.68 ± 0.26
Values are presented as mean ± standard deviation or numbers and percentages (%)
Bpm beats per minute, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, PCI percutaneous
coronary intervention, PTCA percutaneous transluminal coronary angioplasty
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to 69.4 ± 8.8 bpm, while the heart rate in
patients without a previous PCI dropped from
87.0 ± 13.2 bpm to 72.5 ± 10.6 bpm. The
decrease in heart rate was maintained in the 2
subgroups over the study, and the heart rates for
the previous PCI and no previous PCI subgroups
at 4 months were 64.4 ± 7.6 bpm and
66.8 ± 8.5 bpm, respectively (P\0.0001 for all
changes in both subgroups). The mean daily
dose of ivabradine increased in both subgroups
over the 4-month study period to
12.6 ± 2.9 mg/day and 12.1 ± 3.0 mg/day for
patients with and without a PCI, respectively.
The number of angina attacks experienced
by patients with a history of PCI was slightly
higher at baseline at 1.9 ± 2.4 per week vs.
1.5 ± 2.0 per week in patients without.
However, a substantial and similar decrease in
the number of weekly angina attacks was
observed in both subgroups after 1 month
dropping 2.7-fold to 0.7 ± 1.4 and threefold
to 0.5 ± 1.1 for the previous PCI and no
previous PCI subgroups, respectively (Fig. 2).
By 4 months, the number of angina attacks
had further dropped to comparable levels in
patients with a PCI (0.3 ± 1.0 attacks per week)
and patients without (0.2 ± 0.7 attacks per
week; P\0.0001 for all changes in both
subgroups). The drop in the number of
angina attacks was reflected by a similar
decrease in the use of short-acting nitrates. At
baseline, patients with a previous PCI used
nitrate more often (2.7 ± 3.7 times per week)
than patients without (1.8 ± 2.8 times per
week). After 1 month, nitrate usage dropped
to 1.0 ± 1.9 and 0.6 ± 1.5 times per week in
patients with and without a PCI, respectively
(Fig. 2). The decrease in nitrate usage
continued at a comparable rate in both
subgroups, so that by 4 months patients with
and without a PCI were using nitrates at
similar frequencies, 0.5 ± 1.5 and 0.3 ± 1.0
times per week (P\0.0001 for all changes in
both subgroups).
The severity of angina was also assessed in
both groups using the CCS scale. At baseline,
twice the number of patients without a previous
PCI (39.7%) had CCS class I angina than
Fig. 1 Reduction in resting heart rate with initiation of
ivabradine in patients with stable angina on top of optimal
medical therapy including beta-blockers who underwent
previous percutaneous coronary intervention (PCI) and
those who did not (No PCI). P value describes change
between baseline and month 1 and baseline and month 4
for both subgroups. bpm beats per minute
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patients with a previous PCI (19.5%; Fig. 3).
Most patients were in CCS class II angina
(55.4% with a PCI and 45.8% without). After
4 months of treatment, there was a substantial
shift of patients to CCS class I in both subgroups
from 19.5% to 65.2% in patients with a PCI and
39.7% to 71.1% in patients without. Notably,
the combined proportion of patients in the
previous PCI subgroup who moved into CCS
class III and IV dropped by 21.2% after
4 months in comparison with an 11.1% drop
in the no previous PCI subgroup (P\0.0001 for
changes in each CCS Class).
After 4 months, the EQ-5D score indicated
that patient QoL had improved in both
subgroups increasing from 0.65 ± 0.28 to
0.83 ± 0.20 in patients with a previous PCI
and 0.68 ± 0.26 to 0.82 ± 0.20 for patients
without (P\0.0001 for all changes in both
subgroups; Fig. 4). QoL improved slightly more
in the previous PCI subgroup (27.8%) than in
the no previous PCI group (21.9%). The final
Fig. 2 Number of angina attacks (a) and use of short-
acting nitrates (b) per week in post-PCI and no PCI stable
angina patients. P value describes change between baseline
and month 1 and baseline and month 4 for both
subgroups. PCI percutaneous coronary intervention
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VAS scores indicated an improvement in QoL in
all patients with slightly better improvement in
scores in patients with a previous PCI (28.7%)
vs. those without (24.5%; 56.2 ± 18.1 to
72.3 ± 15.2 vs. 58.7 ± 18.5 to 73.1 ± 15.6,
respectively).
The efficacy of ivabradine in patients with a
baseline heart rate of\70 bpm vs. C70 bpm, in
terms of the absolute and relative reduction in
the frequency of angina attacks, nitrate
consumption, and heart rate, was also
evaluated. In the previous PCI subgroup,
Fig. 3 Change in severity of angina from baseline to
4 months, according to CCS class, in post-PCI and no
PCI stable angina patients. P value describes the change
between baseline and month 1 (data not shown) and
baseline and month 4 for each CCS class. CCS Canadian
cardiovascular society, PCI percutaneous coronary
intervention
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patients with a baseline heart rate C70 bpm had
similar absolute decrease in angina attacks at
month 1 (-1.3 ± 1.7 vs. -1.1 ± 2.4 per week)
and month 4 (-1.6 ± 1.9 vs. -1.7 ± 2.9 per
week) than those with a baseline heart rate
\70 bpm (Table 2). However, there was a more
pronounced absolute reduction in the use of
nitrates per week at month 4 for patients with a
baseline heart rate of C70 bpm than those with
a baseline heart rate of\70 bpm (-2.3 ± 3.1 vs.
-1.7 ± 5.0). There was a large difference in the
absolute change in heart rate for patients with a
baseline heart rate of C70 bpm vs. \70 bpm at
month 1 (-14.6 ± 8.7 vs. -2.9 ± 7.3 bpm) and
at month 4 (-19.9 ± 9.8 vs. -5.0 ± 6.9 bpm).
Patients with a baseline heart rate of C70 bpm
were on a higher daily dose of ivabradine
(12.7 ± 2.8 mg) during the study than patients
with a baseline heart rate of \70 bpm
(10.9 ± 2.8 mg). There was a greater relative
reduction in the number of angina attacks per
week in patients with a baseline heart C70 bpm
in comparison with patients who had a baseline
heart rate of \70 bpm at month 1 (70.7% vs.
Fig. 4 Change in quality of life index (EQ-5d) (a) and
EQ-5d visual analog scale score (b) in post-PCI and no
PCI stable angina patients. P value describes change
between baseline and month 1 and baseline and month
4 for both subgroups. PCI percutaneous coronary
intervention, VAS Visual analog scale
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49.2%) and at month 4 (87.5% vs. 67.0%;
Fig. 5). A larger relative reduction in weekly
nitrate consumption was also observed for
patients with a baseline heart rate C70 bpm vs.
\70 bpm at month 1 (70.0% vs. 57.3%) and 4
(86.9% vs. 60.7%). Patients with a baseline heart
rate C70 bpm also had a considerably greater
relative reduction in heart rate than patients
with a baseline heart rate of\70 bpm at month
1 (16.8% vs.4.1%) and month 4 (22.9% vs.
7.3%).
Investigators Assessment
The effectiveness and tolerability of ivabradine
were assessed as either ‘‘very good’’ or ‘‘good’’ by
treating physicians for over 96% of all patients.
No differences in either effectiveness or
tolerability were observed by the physicians
between the two subgroups (Table 3). For the
majority of patients with and without a
previous PCI (97.8% and 96.6%, respectively),
treating physicians categorized ivabradine
effectiveness as either ‘‘very good’’ or ‘‘good’’.
Similarly, physicians classified ivabradine
tolerability as either ‘‘very good’’ or ‘‘good’’ for
over 99% of patients in each of the two
subgroups.
Safety
Fourteen patients (0.6%; see Table 4 for
subgroup data) experienced an adverse drug
reaction during the 4-month study period in the
total cohort, the most common of which were
the presence of phosphenes in the eye (0.13%)
and dizziness (0.13%). Other reported adverse
drug reactions were palpitations (0.09%),
headaches (0.04%), and bradycardia (0.04%).
There were no reported cases of death or non-
fatal MI. No serious adverse drug reactions were
reported during the study.
DISCUSSION
This analysis has shown that treating stable
angina pectoris patients with a combination of
ivabradine and beta-blockers lowered heart rate
and reduced the frequency of angina symptoms
to the extent that CCS classification and QoL
Table 2 Absolute reduction in angina attacks, nitrate use,
and heart rate and mean daily ivabradine dose in the









Angina attacks (per week)








Nitrate use (per week)

















Daily ivabradine dose (mg)








Values are presented as mean ± standard deviation
bpm beat per minute, PCI percutaneous coronary
intervention
130 Adv Ther (2015) 32:120–137
improved independently of PCI status
(P\0.0001 for all changes). Ivabradine was
well tolerated by patients in both subgroups.
These results are consistent with the findings of
a pooled analysis of randomized trials assessing
the effect of ivabradine in various
subpopulations of angina pectoris patients
including those with a previous PCI [26].
PCI alleviates symptoms of angina by a local
approach, as it directly removes defined,
Table 4 The most frequently reported adverse drug
reactions, according to PCI status, classiﬁed using













3 (0.3%) 0 (0.0%)
Dizziness 0 (0.0%) 3 (0.3%)
Palpitations 1 (0.1%) 1 (0.1%)
Bradycardia 1 (0.1%) 0 (0.0%)
Values are patient numbers and percentages (%)
PCI percutaneous coronary intervention
Fig. 5 Relative reduction in the number of angina attacks
per week (a) and use of short-acting nitrates (b) per week
and heart rate (c) in patients with stable angina in the
post-PCI group according to baseline heart rate. PCI
percutaneous coronary intervention
Table 3 Physician assessment of the effectiveness and
tolerability of ivabradine after 4 months in the







Effectiveness 1,170 (98%) 1,109 (98%)
Very good 732 (63%) 662 (60%)
Good 412 (35%) 409 (37%)
Moderate 25 (2%) 36 (3%)
Bad 1 (\1%) 2 (\1%)
Tolerability 1,136 (95%) 1,065 (95%)
Very good 805 (71%) 768 (72%)
Good 328 (29%) 295 (28%)
Moderate 2 (\1%) 2 (\1%)
Bad 1 (\1%) 0 (0%)
Values are patient numbers and percentages (%)
PCI percutaneous coronary intervention
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hemodynamically compromising lesions [27]. It
has an important role to play in the treatment
of lifestyle-limiting angina [28]. However, as our
results indicate, angina symptoms can recur in a
large proportion (51%) of post-PCI patients [24].
In this study, 26% of the previous PCI group
had received 2 or more stents and despite this
they still suffered symptoms of angina.
Recurrent symptoms were also reported in a
study in a Swedish population where more than
half of the women and a third of the men
experienced angina symptoms 4 years after
undergoing a PCI [12]. This was also
confirmed by findings from the COURAGE
trial, where 41% of patients had angina 3 years
after PCI treatment [10].
As CAD is a diffuse disease process,
frequently involving the entire coronary
vasculature, it is more likely to benefit from
systemic treatments such as medical therapy
[29]. This, combined with the fact that PCI does
not lessen the risk of death or other
cardiovascular outcomes in comparison with
medical therapy alone [14], suggests that
optimal medical therapy for the treatment of
stable angina should be pursued from the outset
[14, 18, 30] and is a course of action for
symptom control currently recommended by
the European and American guidelines for the
treatment of CAD [2, 3].
Heart rate is now believed to have a
fundamental role in ischemia and angina. An
elevated heart rate increases myocardial oxygen
demand and reduces diastolic time, these effects
can limit myocardial perfusion leading to
ischemia and, in turn, triggering angina [20,
31]. In patients with stable CAD, an elevated
mean heart rate often precedes myocardial
ischemia and is associated with a higher risk of
cardiovascular events [32–34]. Therefore,
medical therapies that effectively reduce heart
rate merit serious consideration, but are
currently under-prescribed in the treatment of
CAD and stable angina [35].
Ivabradine reduces heart rate by specifically
inhibiting the If current, but does not affect
blood pressure or other cardiac parameters. In
reducing heart rate, ivabradine leads to a
decrease in myocardial oxygen consumption
and an increase in myocardial perfusion,
thereby improving cardiac efficiency [36].
Furthermore, ivabradine maintains the
coronary vasodilation that occurs during
exercise [37]. The results of a placebo-
controlled randomized study showed that
ivabradine improves coronary collateral
function in patients with stable CAD, which
was accompanied by diminished ECG signs of
ischemia [38]. In contrast, beta-blockers—owing
to their negative effect on myocardial
contractility—prolong systole, reducing their
beneficial effect on diastolic time. Beta-
blockers may also affect vasomotion in the
coronary circulation by unmasking alpha-
adrenergic vasoconstriction resulting in
constriction of large and small coronary
arteries during exercise [39]. Ivabradine has
been shown to be an effective anti-anginal
agent either as a stand-alone or as a
combination therapy including beta-blockers
[21, 40]. Despite the fact that several
guidelines recommend a target heart rate
below 60 bpm in patients with angina [2, 3],
the CLARIFY (Controlled-Trials.com
#ISRCTN43070564) registry revealed that only
22% of angina patients on beta-blockers
achieved an optimal heart rate. Thus, many
patients with still elevated heart rate could
benefit from the addition of ivabradine to
their treatment [41].
In the ADDITIONS study, the addition of
ivabradine led to a further substantial reduction
in resting heart rate without excessive
bradycardia. The effect was significant within
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the first 4 weeks of treatment despite prior and
ongoing beta-blocker therapy. The effect of
ivabradine was more pronounced in patients
who had a baseline heart rate of C70 bpm. The
relative reduction in the number of angina
attacks and short-acting nitrate consumption
was substantially larger in patients with a
baseline heart rate of C70 bpm than \70 bpm
at 1 month and 4 months. These data are in line
with the pharmacological use-dependent
properties of ivabradine, and therefore patients
with a higher heart rate will benefit most from
therapy with ivabradine [42]. This is also in line
with new recommendations from the European
Medicines Agency (EMA) to initiate ivabradine
therapy in patients with angina with a heart
rate of C70 bpm.
QoL has been shown to be worse in patients
with stable angina than in those without [43].
In this post hoc analysis, treatment with
ivabradine was associated with improved QoL
in patients with stable angina. The CADENCE
(Coronary Artery Disease in General Practice;
ANZCTR.org.au #ACTRN12608000347369)
study reported that 29% of stable angina
patients experienced weekly angina (C1
episode per week) and had a poorer QoL than
patients who experienced angina less than once
a week [44]. These results correlate with our
findings where the mean frequency of angina
attacks dropped from [1 to \1 attack per week
and patient QoL improved congruently. QoL is
an important factor to be kept in mind when
assessing the effectiveness of CAD treatment.
The Society of Cardiovascular Angiography
recommends that QoL be considered as an
outcome in clinical trials and physicians care
[45]. While PCI improves patient QoL in the
short term, it is often proportional to the
severity of angina symptoms and there is less
evidence supporting the benefits of PCI in the
presence of severe comorbidities [45]. The
results of this post hoc analysis of ADDITIONS
have demonstrated that combining ivabradine
with beta-blocker in daily clinical practice
reduces symptoms, improves CCS classification
and also the QoL in patients with stable angina
pectoris after PCI.
The recent data from the SIGNIFY (Study
assessInG the morbidity–mortality beNefits of
the If inhibitor ivabradine in patients with
coronarY artery disease, Controlled-Trials.com
#ISRCTN61576291) trial, conducted in patients
with CAD on optimal medical treatment
without clinical heart failure, did not
demonstrate an effect of ivabradine on the
incidence of the primary combined endpoint
of cardiovascular death and non-fatal MI [46].
In a pre-specified subgroup of symptomatic
angina patients, there was a small, but
statistically significant, increase in the
incidence of the primary endpoint with no
significant effects for the individual
components of the primary endpoint. The
incidence of bradycardia was the highest ever
reported in any ivabradine trial (ivabradine,
18.0% vs. placebo, 2.3%; P\0.001). However,
in the SIGNIFY trial a therapeutic regimen that
is not approved for clinical use was applied,
which included a higher initiation and
uptitration dose (7.5 and 10 mg bid,
respectively). The EMA conducted a review of
ivabradine and made recommendations aimed
at reducing the risk when using ivabradine in
patients with angina. These recommendations
included the importance of respecting the
recommended dosage regimen—the starting
dose should not exceed 5 mg, twice daily, and
the maximum dose should not exceed 7.5 mg,
twice daily. Furthermore, ivabradine should
only be prescribed for patients with a resting
heart rate of C70 bpm, with a contraindication
for the concomitant use of ivabradine with
diltiazem or verapamil [47].
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Regarding the safety profile of ivabradine in
our study, only mild adverse drug reactions
were reported in 0.6% of all patients. There were
no reported cases of death, non-fatal MI or
serious adverse drug reactions during the study.
A limitation of the study was its short
duration (4 months) and that it was open label.
There was also no placebo group to support the
observed effect of treatment. Adherence to the
treatment was not formally evaluated, though
the significant reduction in heart rate observed
throughout the study indicates good adherence.
The frequency of weekly angina attacks and
nitrate consumption was measured for only
1 week prior to the study visits. This was due,
in part, to the non-interventional design of the
study but also to avoid poor or inaccurate
symptom recall by patients, which could occur
over a longer period of time. Nevertheless,
reporting/recall bias to some extent cannot be
ruled out, but this may in part also be
compensated using different measures of
effectiveness (number of attacks, nitrate use,
QoL). The missing placebo group, presence of
possible reporting bias, and also relatively high
resting heart rate at baseline in both patient
groups (ivabradine effects are more pronounced
with higher heart rate) can lead to an
overestimation of the treatment benefit. On
the other hand, ivabradine is often used in
these high heart rates in practice, thus reflecting
current clinical use of the compound. Only half
of the patients were uptitrated to the
recommended maximal dose (7.5 mg twice
daily). Although it is not possible to say to
which extent the symptomatic benefit may have
increased in this study population by intensified
uptitration, it has been demonstrated that heart
rate lowering and anti-anginal effects of
ivabradine are clearly dose dependent up to
7.5 mg twice daily [20]. Another limitation of
the study regarding specifically the sub-analysis
of patients with PCI according to baseline heart
rate (\70 bpm or C70 bpm) is the small number
of patients with baseline heart rate \70 bpm
(n = 94). But it should be noted that ivabradine
is not to be used in angina patients with baseline
heart rate below 70 bpm according to recent
EMA recommendations and European Union
indication. Focus of this analysis is therefore
clearly the patient cohort with heart rate
C70 bpm. The main strength of this study was
that it was undertaken in a large population of
stable angina patients, who were already
receiving optimized medical therapy, in over
800 centers in Germany. Moreover, the non-
interventional study design supported an
evaluation of treatment effects under
conditions of routine clinical practice, taking
into account patient subgroups that are usually
excluded from clinical trials, such as elderly
patients or patients with multiple comorbidities.
CONCLUSIONS
The addition of ivabradine to medical therapy,
including beta-blockers, for the treatment of
stable angina was effective and well tolerated,
independent of PCI status. Many patients with a
previous PCI have recurring symptoms of
angina. Ivabradine should be considered as an
important therapeutical option in the
treatment of symptomatic stable angina as it
reduced the frequency of weekly angina attacks
and nitrate usage, led to an improvement in
CCS class and a substantial improvement in the
QoL of patients with stable angina.
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